Semaglutide Patent Expiry: Indian Pharma Race Begins, Prices May Drop 70%

A New Era for Diabetes and Obesity Treatment in India

The patent for semaglutide, the active pharmaceutical ingredient in Novo Nordisk's widely used drugs Ozempic, Wegovy, and Rybelsus, expired in India on March 20, 2026. This event marks a significant turning point for the treatment of type 2 diabetes and obesity in the country, as it opens the market to a wave of generic competition. Starting March 21, several major Indian pharmaceutical companies are set to launch their own versions of the drug, a move expected to drastically reduce treatment costs and improve accessibility for millions of patients.

The Starting Gun Fires for Generic Competition

With the patent barrier lifted, a fierce race for market share is underway. Domestic pharmaceutical giants including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, and Mankind Pharma have confirmed their plans for 'Day 1' launches. Industry estimates suggest that over 50 branded generic versions of semaglutide could enter the Indian market in the coming months. This scenario mirrors the patent expiry of the diabetes drug sitagliptin in 2022, which saw nearly 100 branded generics flood the market within a year. The Indian GLP-1 market, which semaglutide dominates, has already surpassed ₹1,000 crore in annual sales, and analysts project that generic semaglutide could create an incremental market opportunity of over ₹5,000 crore within the next 12 to 15 months.

Anticipated Price Reduction and Market Impact

The most immediate and significant impact for patients will be a sharp reduction in cost. The current monthly therapy cost for innovator semaglutide ranges from ₹10,000 to ₹12,000. With the entry of generics, analysts predict prices could fall by 50% to 70%, bringing the monthly cost down to a more manageable ₹3,000 to ₹5,000. Sheetal Sapale, Vice President at Pharmarack, noted that prices of generic drugs typically fall to one-third or even one-fifth of the innovator's price, leading to a substantial increase in patient adoption.

Key Players and Their Launch Strategies

Leading Indian pharma companies have been preparing for this moment for months, each adopting a distinct strategy to capture a piece of this lucrative market.

• Sun Pharmaceutical Industries: Leveraging its extensive manufacturing capabilities and one of the largest sales forces in the country, Sun Pharma is launching two brands: 'Noveltreat' for chronic weight management and 'Sematrinity' for type 2 diabetes. The company has already secured approval from the Drugs Controller General of India (DCGI).

• Dr. Reddy's Laboratories: Dr. Reddy's has also confirmed a Day 1 launch, positioning its generic semaglutide as part of a comprehensive metabolic health portfolio that includes patient support programs and nutritional products.

• Zydus Lifesciences: Zydus is entering the market with multiple brands, including SEMAGLYN and MASHEMA. The company aims to differentiate itself with an indigenously developed reusable, adjustable pen device, which could further reduce costs and improve patient convenience. Zydus is also acting as a manufacturing partner for other players like Lupin and Torrent Pharmaceuticals.

• Mankind Pharma: Known for its strong distribution network that reaches smaller towns, Mankind Pharma is launching its version under the brand name 'Samakind', targeting physicians across diabetes, obesity, and cardiovascular segments.

Addressing a Major Health Challenge

The availability of affordable semaglutide is critical for India, a country with over 100 million people living with diabetes and a rapidly growing obesity epidemic. Dr. Unnikrishnan A G, Chief Endocrinologist at Chellaram Diabetes Institute, highlighted the growing patient interest in GLP-1 therapies and stated that improved accessibility will help address significant unmet medical needs. While initial adoption is expected to be led by diabetes treatment, demand for weight management is anticipated to grow, particularly in urban areas.

Manufacturing Hurdles and Innovator's Defense

Despite the enthusiasm, the rollout of generic semaglutide is not without challenges. The drug is a complex peptide that requires specialized manufacturing processes and delivery systems like prefilled pens. According to industry observer Salil Kallianpur, these complexities could limit how quickly companies can scale up production initially, giving an early advantage to firms with existing peptide manufacturing expertise. Meanwhile, the innovator, Novo Nordisk, is not standing idle. The Danish company has preemptively partnered with Abbott in India to co-market its semaglutide products, aiming to expand its reach and defend its market share against the incoming generic wave.

The Road Ahead

The expiry of the semaglutide patent is set to reshape the landscape of metabolic disease management in India. While affordability will remain a consideration in a healthcare system dominated by out-of-pocket expenses, the dramatic price drop will undoubtedly expand access to a highly effective therapy. The intense competition among dozens of generic brands will likely lead to further price compression over time, benefiting a larger segment of the population and marking a pivotal moment in India's fight against diabetes and obesity.